Study Summary
This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive acute leukemia.
Interested in this trial?
Submit an InquiryInterventions
Humanized CD7 CAR-T cellsBIOLOGICAL
Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (0.5-10)x10\^6 CD7 CAR-T cells/kg
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Soochow University | Suzhou | (Select) | China |